Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biopsych.2018.07.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ENIGMA-Meditation: Worldwide consortium for neuroscientific investigations of meditation practices.
Biol Psychiatry Cogn Neurosci Neuroimaging
November 2024
Department of Psychiatry and Behavioral Health, The Ohio State University College of Medicine, Columbus, OH, USA; Department of Psychology, The Ohio State University, Columbus, OH, 43210, USA; Center for Cognitive and Behavioral Brain Imaging, Department of Psychology, The Ohio State University, Columbus, OH, 43210, USA; Institute for Behavioral Medicine Research, Ohio State University Medical Center, Columbus, OH, USA; Institute for Behavioral Medicine Research, Ohio State University Medical Center, Columbus, OH, USA. Electronic address:
Meditation is a family of ancient and contemporary contemplative mind-body practices that can modulate psychological processes, awareness, and mental states. Over the last 40 years, clinical science has manualised meditation practices and designed various meditation interventions (MIs), that have shown therapeutic efficacy for disorders including depression, pain, addiction, and anxiety. Over the past decade, neuroimaging has examined the neuroscientific basis of meditation practices, effects, states, and outcomes for clinical and non-clinical populations.
View Article and Find Full Text PDFCross-continental environmental and genome-wide association study on children and adolescent anxiety and depression.
Front Psychiatry
May 2024
Tri-Institutional Center for Translational Research in NeuroImaging and Data Science, Atlanta, GA, United States.
Anxiety and depression in children and adolescents warrant special attention as a public health concern given their devastating and long-term effects on development and mental health. Multiple factors, ranging from genetic vulnerabilities to environmental stressors, influence the risk for the disorders. This study aimed to understand how environmental factors and genomics affect children and adolescents anxiety and depression across three cohorts: Adolescent Brain and Cognitive Development Study (US, age of 9-10; N=11,875), Consortium on Vulnerability to Externalizing Disorders and Addictions (INDIA, age of 6-17; N=4,326) and IMAGEN (EUROPE, age of 14; N=1888).
View Article and Find Full Text PDFMulti-trial, aggregated, individual participant data mega-analysis of short-term antidepressant versus mood stabilizer monotherapy of bipolar type II major depressive episode.
Bipolar Disord
May 2024
Department of Psychology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Background: Few studies have systematically examined the safety and effectiveness of antidepressant versus mood stabilizer monotherapy of bipolar II depression. To date, there are no aggregated or mega-analyses of prospective trials of individual participant-level data (IPD) to inform future treatment guidelines on the relative safety and effectiveness of antidepressant or lithium monotherapy.
Methods: Data from a series of four independent, similarly designed trials of antidepressant or lithium monotherapy (where longitudinal IPD were available) (n = 393) were aggregated into an IPD dataset (i.
Cortical morphology in patients with the deficit and non-deficit syndrome of schizophrenia: a worldwide meta- and mega-analyses.
Mol Psychiatry
October 2023
Neuropsychiatry Laboratory, Department of Clinical Neuroscience and Neurorehabilitation, IRCCS Santa Lucia Foundation, Rome, Italy.
Converging evidence suggests that schizophrenia (SZ) with primary, enduring negative symptoms (i.e., Deficit SZ (DSZ)) represents a distinct entity within the SZ spectrum while the neurobiological underpinnings remain undetermined.
View Article and Find Full Text PDFEfficacy of Serotonin and Dopamine Activity Modulators in the Treatment of Negative Symptoms in Schizophrenia: A Rapid Review.
Biomedicines
March 2023
Department of Neuroscience "Rita Levi Montalcini", University of Turin, 10124 Torino, Italy.
Schizophrenia is among the fifteen most disabling diseases worldwide. Negative symptoms (NS) are highly prevalent in schizophrenia, negatively affect the functional outcome of the disorder, and their treatment is difficult and rarely specifically investigated. Serotonin-dopamine activity modulators (SDAMs), of which aripiprazole, cariprazine, brexpiprazole, and lumateperone were approved for schizophrenia treatment, represent a possible therapy to reduce NS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!